Floatz logo

Oxodotreotide

Metastatic Pancreatic Neuroendocrine Tumor

University of Chicagoprotein_peptidePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
95/ 100

Competitive context

40 Active assets in the Metastatic Pancreatic Neuroendocrine Tumor cohort.

Asset / SponsorPhaseRating
Everolimus
Exelixis
Phase 4BBB
Irinotecan
M.D. Anderson Cancer Center
Phase 2/3BB
Oxodotreotide
National Cancer Institute (NCI)
Phase 4BB
Octreotide Pamoate
RayzeBio, Inc.
Phase 3BB
FLUOROURACILUM
H. Lee Moffitt Cancer Center and Research Institute
Phase 2/3BB

View all 50 →

Same molecule, other indications

Oxodotreotide is also rated in:

digestive system neuroendocrine neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
digestive system neuroendocrine tumor, grade 1/2Dormant
BB
Indicative ·
69 / 100
View asset →
pancreatic neuroendocrine tumorDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →